We connect China's market with global medical resources to find the right medicines for Chinese patients — focusing on high-barrier drug licensing across oncology, cardiovascular, CNS, antiviral, gastrointestinal and endocrine therapeutic areas.
成熟制剂 License in、自研产品 License out、面向 CGT 早研项目的种子孵化服务。
License-in of mature formulations, License-out of self-developed products, and incubation for early-stage CGT projects.
提供中国市场竞争机会评估、进口注册申报、市场推广与多渠道组合销售。
China market opportunity assessment, import registration, and multi-channel promotion.
近专利期重磅药物，已完成 API 与制剂开发，部分已在半法规市场获批或已在中国申报。
Near-cliff blockbusters with completed API and formulation development; some approved in semi-regulated markets or filed in China.
筛选国内 CGT 方向早研项目孵化，提供 S&E、IP、BD、FA、PM 系列专业服务。
Incubating early-stage CGT projects with S&E, IP, BD, FA and PM support.
从机会评估、进口注册到多渠道销售，奥祺提供一站式落地服务。
From opportunity assessment and import registration to multi-channel sales — Aoqi delivers end to end.
Contact Us →